Abstract

Background

In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.

Methods

The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).

Results

Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24–0.57) and at age >18 years was 0.82 (CI, 0.67–0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.

Conclusions

Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.

中文翻译：

---

美国对男性和男性的肛门和口腔样本中人类乳头瘤病毒感染DNA流行的疫苗有效性-美国，2016-2018年。

摘要

背景

自2011年以来，在美国，建议对与男性发生性行为的成年男性（MSM）进行人乳头瘤病毒（HPV）疫苗接种。

方法

《男性疫苗影响力》研究调查了2016-2018年间美国3个城市中18-26岁的MSM和跨性别女性。自我收集的肛门拭子和口腔冲洗标本评估了37种HPV类型。我们比较了接种疫苗者和未接种疫苗者的HPV患病率，并确定了调整后的患病率（aPR）和95％置信区间（CI）。

结果

在1767名参与者中，有704名（39.8％）自我报告接受HPV疫苗。接种疫苗的中位年龄（18.7岁）比初次性交年龄（15.7岁）大。在来自475名（26.9％）参与者的肛门或口腔样本中检测到四价疫苗型HPV。与未接种疫苗的参与者（31.6％）相比，接种疫苗的疫苗类型HPV患病率较低（22.9％）；≤18岁开始接种疫苗的人的aPR为0.41（CI，0.24-0.57），大于18岁开始接种的人的aPR为0.82（CI，0.67-0.98）。≤18岁或大于18岁的至少1株HPV疫苗的疫苗有效性分别为59％和18％。

结论

研究结果表明，在年轻成人MSM中进行HPV疫苗接种具有现实效果。接种疫苗的年龄越小，这种作用越强。